[카이노스메드 제공. 재판매 및 DB 금지]
(Seoul = Yonhap News) Reporter Yoo Seon-hyun = Kino Med[284620]announced on the 28th that it has started joint research with MDMMune, a drug delivery platform developer, to develop an anticancer drug loaded with the apoptosis inhibitor ‘FAF1’ in the form of messenger ribonucleic acid (mRNA) and protein.
To this end, KinoSmed will receive the cell-derived vesicles (CDV)-based platform ‘Bio-Drone’ technology from MD-Mune. CDV is a drug delivery system capable of loading various genetic materials, and has characteristics similar to cell-derived material ‘exosome’, which acts as an information carrier between cells.
KinoSmed recently confirmed that tumor size was reduced when FAF1 was loaded onto exosomes and delivered to cancer cells and mouse cancer tissues.
Through this research and technology transfer contract, KinoSmed plans to explore a way to deliver FAF1 in the form of mRNA to prevent overexpression before it is delivered to target cells.
key@yna.co.kr
<저작권자(c) 연합뉴스,
Unauthorized reproduction-redistribution prohibited>
2021/10/28 14:46 Send
